NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company specializing in natural killer (NK) cell therapies, operating today as a post-merger public company following its business combination with Graf Acquisition Corp. IV, sponsored by Graf & Company LLC. Graf Acquisition Corp. IV conducted its IPO in 2021, targeting the biotechnology and life sciences sector, and the de-SPAC transaction closed in September 2023. NKGen's pipeline centers on NK cell-based treatments across oncology and neurodegenerative indications, including Alzheimer's disease. The company filed an 8-K with the SEC on February 25, 2025, under accession number 0001213900-25-017098. Sign up at SpacDesk for full filing history, deal analytics, and real-time data on NKGN and the broader SPAC universe.